Spectrum Of Activity
HIV infection 1 film-coated tab (400 mg) PO q12h
If co-administrated with Rifampin, 800 mg PO q12hNo renal dose adjustmentChewable tablets and oral suspension are not interchangeable with film-coated tablets.
Safety and efficacy in pediatric patients <4w of age have not been established
BW 3-4 kg: oral suspension 20 mg PO q12h
BW 4-6 kg: oral suspension 30 mg PO q12h
BW 6-8 kg: oral suspension 40 mg PO q12h
BW 8-11 kg: oral suspension 60 mg PO q12h
BW 11-14 kg: oral suspension 80 mg PO q12h
BW 14-20 kg: oral suspension 100 mg or 1 chewable tab (100 mg) PO q12h
BW 20-25 kg: 1.5 chewable tab PO q12h
BW >25 kg: 1 film-coated tab (400 mg) PO q12hNo renal dose adjustmentChewable tablets and oral suspension are not interchangeable with film-coated tablets.
Mild or moderate hepatic impairment No dose adjustment
Severe hepatic impairment No data
Treatment for HIV infection and used as part of a 3-drug combination regimen.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT,AST, and total bilirubin.
Monitor fasting blood glucose or HbA1c at baseline and with modification of ARV treatment.
Toxic epidermal necrolysis
Al or Mg antacids
Medications containing polyvalent cations
Antimicrobial class: Antiretroviral agent, Integrase Inhibitor
Pregnancy category: C
Average serum half life: 9 hours
Precautions: Discontinue use immediately if signs or symptoms of skin reactions develop.
Immune reconstitution syndrome has been reported; monitoring recommended; further evaluation and treatment of opportunistic infections may be necessary.
Chewable tablets contain phenylalanine.